论文部分内容阅读
本文作者为胰癌诊断制作了新的单克隆抗体——KM_(01)抗体,认为它与CA19-9抗体有同样的临床应用价值.作者用同一血清标本检测KM_(01)、CA10-9及CEA对各种疾病的阳性率:胰癌对KM_(01),为79.3%,CA10-981.8%,CEA41.4%.在慢性胰腺炎KM_(01)、CA10-9、CEA各为20.0%、16.6%、21.7%;对胰腺疾病KM_(01)和CA10-9几乎显示同样的阳性率.大肠癌KM_(01)为31.8%,CA_(10)-934.9%.值得注目的是肝癌时KM_(01)阳性率为50%,比CA10-9的11.9%有意义.作者为对肿瘤标志物作广义的和狭义的比较,测定胰癌42例、慢性胰腺炎22例,用同一血清进行比较.CA10-9、KM_(01)阳性率最高,其次是FER(铁蛋白)70.0%,AAT(α_1抗胰蛋白酶)60.7%,IAP(免疫抑制蛋白)60.0%,TF(输铁蛋白)59.3%.肿瘤相关抗原FER、AAT、IAP对
The authors developed a new monoclonal antibody, KM_(01), for the diagnosis of pancreatic cancer, which is considered to have the same clinical value as the CA19-9 antibody. The authors used the same serum sample to detect KM_(01), CA10-9, and The positive rate of CEA in various diseases: pancreatic cancer KM_(01) was 79.3%, CA10-981.8%, CEA 41.4%. In chronic pancreatitis KM_(01), CA10-9, CEA were 20.0% each, 16.6%, 21.7%; almost the same positive rate for pancreatic diseases KM_(01) and CA10-9. Colorectal cancer KM_(01) is 31.8%, CA_(10)-934.9%. It is worth noting that KM_ ( 01) The positive rate is 50%, which is significant compared with 11.9% of CA10-9. The authors make a broad and narrow comparison of tumor markers. 42 cases of pancreatic cancer and 22 cases of chronic pancreatitis were compared with the same serum. The positive rates of CA10-9 and KM_(01) were the highest, followed by FER (ferritin) 70.0%, AAT (α_1 antitrypsin) 60.7%, IAP (immunosuppressive protein) 60.0%, and TF (transferrin) 59.3%. Tumor-associated antigen FER, AAT, IAP pairs